Author:
Heather Eleanor M.,Payne Katherine,Harrison Mark,Symmons Deborah P. M.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference126 articles.
1. National Institute for Health and Clinical Excellence. Assumptions used in estimating a population benchmark. http://www.nice.org.uk/usingguidance/commissioningguides/raadults/raserviceassumptions.jsp . Accessed 4 June 2012.
2. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis. 2004;63(1):4–10.
3. National Rheumatoid Arthritis Society. http://www.nras.org.uk/about_rheumatoid_arthritis/default.aspx . Accessed 10 July 2012.
4. van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res. 2011;63(1):65–78.
5. Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewe R, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:955–1003.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献